

Dispersome®

Make your drugs soluble

Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.

Beta-lactoglobulin as pharmaceutical excipient

Proteins comprise a new group of excipients for preparing amorphous solid dispersions. Beta-lactoglobulin (BLG), the main component in Dispersomes, results in superior drug solubility compared to other proteins. Zerion Pharma has a strong IP portfolio covering protein-based excipients for solid dispersions with patent life beyond 2040.

Stable formulations with high drug loading

The use of Dispersome® technology enables drug loadings above 50% w/w while maintaining stability and improving API solubility. At a drug loading of 50%, stable amorphous formulations are obtained for more than 80% of all drugs tested.

A safe and manufacturable excipient


We work with world leading suppliers to source and qualify our BLG material, ensuring high quality and large scale. BLG is a natural ingredient used in food and nutrition products and is easy to integrate in your existing processes.

Superior outcomes, compatible technology


By increasing drug solubility, the Dispersome® platform aims at improving oral bioavailability and therapeutic outcomes for patients. Dispersome® formulations are compatible with standard pharmaceutical processes and Spray Drying provides a scalable manufacturing solution for Dispersomes.



Dispersome® formulation achieves a superior dissolution rate and better solubility compared to other solid dispersions when addressing a poorly soluble drug, ZN-X



Dispersome® formulations result in a substantial solubility increase for most poorly soluble drugs, compared to the crystalline form of the drug.



Your preferred solubility partner

We invite you to test the performance of our Dispersome® technology in a fast and informative feasibility study. We have successfully used this technology on multiple drug molecules from pharma companies.